Inovio Pharmaceuticals (NASDAQ:INO) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18, Zacks reports. The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.03 million.

Inovio Pharmaceuticals Stock Down 1.0 %

Shares of INO traded down $0.02 during trading hours on Friday, reaching $1.92. 2,019,265 shares of the company traded hands, compared to its average volume of 550,681. The stock has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $3.71. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The stock has a market capitalization of $50.11 million, a PE ratio of -0.48 and a beta of 0.92.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. HC Wainwright reissued a "neutral" rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday. Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a "sector perform" rating on the stock in a research note on Wednesday. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, StockNews.com raised Inovio Pharmaceuticals to a "sell" rating in a research note on Friday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $12.20.

Remove Ads

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.